Breast Cancer News

News

Clinical Decision Support Tool Effective For Early Breast Cancer Treatment

07/28/2021

A new simulation model-based decision tool may be able to support discussion about genomic testing and early breast cancer treatment through its ability to integrate clinicopathologic features, comorbidities, and genomic information.

A new simulation model-based...

07/28/2021

Journal of Clinical Pathways

News

Real-World Impact of Baseline Risk Factors on Incidence of Febrile Neutropenia in Patients With Breast Cancer

07/28/2021

Findings from a real-world study show the choice of febrile neutropenia definition significantly changed the impact of risk factors on febrile neutropenia outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim...

Findings from a real-world study...

07/28/2021

Journal of Clinical Pathways

News

Real-World Practice Patterns for First-Line Treatment of Metastatic Breast Cancer

06/29/2021

Study results show substantial variation in treatment selection and costs for first-line treatment of patients with metastatic breast cancer in Washington State.

Study results show substantial...

06/29/2021

Journal of Clinical Pathways

News

Real-World Adherence to Endocrine Therapy Plus Ovarian Suppression for Early Breast Cancer

04/20/2021

Journal of Clinical Pathways

News

Adjuvant Hormonal Therapy Adherence Low Among Commercially Insured Patients With Breast Cancer

03/12/2021

Journal of Clinical Pathways

News

Researchers Develop Method to Identify High-Value Oncology Care

03/12/2021

Journal of Clinical Pathways

News

Optimizing Germline Genetic Testing for Women With Breast or Ovarian Cancer

03/10/2021

Journal of Clinical Pathways

News

Targeted Genetic Testing Cost-Effective for Breast and Ovarian Cancer

02/08/2021

Journal of Clinical Pathways

News

Circulating Tumor Cell Count Reliable in Determining Best Treatment Approach for Metastatic Breast Cancer

01/14/2021

Journal of Clinical Pathways

News

Real-World Perceptions of Bone-Modifying Agent De-Escalation in Breast and Prostate Cancers

01/13/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Breast Cancer News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products